Q-omics provides the consensus-scored UBE2K profile across patient tissues and cancer cell-line models. UBE2K expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, UBE2K is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, UBE2K RNA expression shows 20,250 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, HNSC, and ACC as cancer lineages where UBE2K shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE2K — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE2K survival associations across molecular data types. UBE2K RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE2K RNA expression–survival associations across cancer types. High UBE2K expression shows unfavorable associations in LIHC, UVM, KICH, PAAD and LUAD, but favorable associations in COAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for UBE2K RNA expression.
This table summarizes UBE2K tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for UBE2K. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE2K shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, LUAD, BRCA and CHOL. The HNSC box plot shows higher UBE2K RNA expression in tumor versus normal tissue (log2 FC = +0.575, t-test p < 0.001).
This table shows molecular features associated with UBE2K in patient tissues and cancer cell lines. In patient samples, UBE2K shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, UBE2K RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
